P. Etienne

发表

Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: tolerance and efficacy.

T. Conroy, S. Gourgou-Bourgade, M. Jarlier, 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

T. Conroy, Y. Bécouarn, O. Bouché, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer

T. Conroy, Y. Bécouarn, O. Bouché, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

EGFR Expression Is Unreliable to Decide for Cetuximab Treatment in Patients with Metastatic Colorectal Cancer: Results from “ERBITUX-OUEST”

J. Douillard, N. Padilla, J. Raoul, 2016 .

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.

P. Rougier, O. Bouché, A. de Gramont, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study

M. Loriot, P. Rougier, O. Bouché, 2015, Molecular Cancer Therapeutics.

Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.

Christophe Hennequin, Bernard Denis, Pierre-Luc Etienne, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ACCORD12/0405-Prodige 2 Phase III Trial Neoadjuvant Treatment in Rectal Cancer: Results after 3 Years of Follow-up

T. Conroy, P. Romestaing, S. Gourgou-Bourgade, 2011 .

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Greil, B. Chauffert, S. Barni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

L. Mineur, A. Kramar, A. Adenis, 2016, BMC Cancer.

Sequential chemotherapy and radiotherapy for patients with squamous cell carcinoma of the esophagus

M. Hassel, J. Raoul, B. Meunier, 1995, Cancer.

Combined radiochemotherapy for postoperative recurrence of oesophageal cancer.

J. Raoul, B. Meunier, B. Launois, 1995, Gut.

Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre

M. Ychou, P. Rougier, R. Guimbaud, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer.

A. Figer, L. Mineur, A. de Gramont, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control

C. Mariette, G. Piessen, A. Kramar, 2016, Oncology.

Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000–05): Preliminary results

M. Ducreux, P. Rougier, O. Bouché, 2007 .

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results

O. Bouché, F. Retornaz, J. Taieb, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Thirteen-Month Registration of Patients with Gastroenteropancreatic Endocrine Tumours in France

W. Cacheux, M. Ducreux, P. Rougier, 2008, Neuroendocrinology.

Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710.

P. Rougier, J. Raoul, J. Seitz, 2009, Endocrine-related cancer.

Evaluation of Nurses’ and Patients’ Overall Satisfaction with New and Previous Formulations of Octreotide Long-acting Release (Sandostatin LAR®): A French Observational Study

I. Sobhani, R. Coriat, S. Bisot-Locard, 2020, Advances in Therapy.

Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial.

O. Bouché, L. Mineur, V. Le Brun-Ly, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.

O. Bouché, F. Retornaz, J. Taieb, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

VINORELBINE IN EPIDERMOID ESOPHAGEAL

T. Conroy, M. Glabbeke, J. Seitz, 2018 .

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.

T. Conroy, C. Borg, V. Boige, 2020, Journal of Clinical Oncology.

Response to the letter “Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU and infusional 5-FU alone in advanced pancreatic carcinoma patients”, by C. Allior (Ann. Oncol 2004; 15: 1576–1577)

M. Ducreux, P. Rougier, J. Breau, 2004 .

3030 POSTER Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000–05): preliminary results

M. Ducreux, P. Rougier, O. Bouché, 2007 .

Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

L. Mineur, A. Kramar, A. Adenis, 2016, BMC Cancer.

702 Randomized phase III trial comparing 5FU bolus and low dose leucovorin versus 5FU bolus plus continuous 5FU infusion and high dose LV in metastatic colorectal cancer

P. Rougier, O. Bouché, L. Bedenne, 1995 .

Influence of age on chemoradiotherapy outcome in patients with rectal cancer: Exploratory analysis from the phase III study ACCORD 12/0405 PRODIGE 2.

T. Conroy, S. Gourgou-Bourgade, C. Hennequin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial.

J. Douillard, V. Boige, O. Bouché, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus

M. Hassel, G. Maddern, B. Meunier, 1994, Cancer.

Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.

O. Bouché, A. Bedjaoui, F. Retornaz, 2018, European journal of cancer.

Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study

C. Lepage, J. Emile, F. Ghiringhelli, 2019, Gut.

Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.

Pierre Michel, Bernard Denis, Pierre-Luc Etienne, 2011, The Lancet. Oncology.

Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer

T. Conroy, D. Peiffert, L. Mineur, 2010, British Journal of Cancer.

Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients.

M. Ducreux, P. Rougier, J. Breau, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Distinct effects of cell-cell communication and corticosteroids on the synthesis and distribution of cytokeratins in cultured rat hepatocytes.

C. Guguen-Guillouzo, P. Loyer, D. Glaise, 1991, Journal of cell science.

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.

T. Conroy, J. Douillard, V. Boige, 2014, The Lancet. Oncology.

T. Conroy, C. Bascoul-Mollevi, J. Douillard, 2017, European journal of cancer.

Randomized multicenter phase III trial comparing two neoadjuvant chemoradiotherapy (CT-RT) regimens (RT45-Cap versus RT50-Capox) in patients (pts) with locally advanced rectal cancer (LARC): Results of the ACCORD 12/0405 PRODIGE 2.

T. Conroy, S. Gourgou-Bourgade, C. Hennequin, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.

T. Conroy, J. Bosset, C. Borg, 2021, The Lancet. Oncology.

VINORELBINE IN EPIDERMOID ESOPHAGEAL CARCINOMA 167

T. Conroy, J. Seitz, A. Adenis, 2017 .

Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.

M. van Glabbeke, T. Conroy, M. Glabbeke, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803.

D. Arsène, P. Rougier, B. Buecher, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival.

T. Gorlia, T. Conroy, E. Van Cutsem, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.

C. Tournigand, M. Buyse, I. Chirivella, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

P. Couzigou, M. Ducreux, C. Borel, 2018, European journal of cancer.

Transient expression of c-fos and constant expression of c-myc in freshly isolated and cultured normal adult rat hepatocytes.

C. Guguen-Guillouzo, D. Glaise, G. Baffet, 1988, Oncogene research.

Phase II/III randomized trial of exclusive chemoradiotherapy with or without dose escalation in locally advanced esophageal carcinoma: The CONCORDE study (PRODIGE 26).

D. Peiffert, F. Bonnetain, J. Seitz, 2016 .

MRI-Based Radiomics Input for Prediction of 2-Year Disease Recurrence in Anal Squamous Cell Carcinoma

N. Magné, Olivier Saut, A. Lièvre, 2021, Cancers.

L. Mineur, A. Kramar, A. Adenis, 2016, BMC Cancer.

Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.

C. Tournigand, M. Buyse, I. Chirivella, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER PRODIGE 23): Health-related quality of life longitudinal analysis.

C. Bascoul-Mollevi, C. Borg, S. Gourgou, 2023, European journal of cancer.

Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology.

T. Conroy, P. Rougier, P. Arveux, 2005, Gastroenterologie clinique et biologique.

Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child–Pugh B cirrhosis

C. Lepage, G. Deplanque, V. Bourcier, 2021, Hepatology International.

Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics

J. Douillard, P. Langlet, E. Jobard, 2014, Oncologie.

ACCORD12/0405-Prodige 2 phase III trial neoadjuvant treatment in rectal cancer: Results after 5 years of follow-up.

T. Conroy, O. Bouché, S. Gourgou-Bourgade, 2016 .

P h ase I I T rial o f Vinorelbine i n M e tastatic Squam o us C ell E sophageal C arcinoma

T. Conroy, J. Seitz, A. Adenis, 1996 .

Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.

E. Van Cutsem, B. Nordlinger, M. Ducreux, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) + ipilimumab (IPI) or nivo + chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer.

J. Ajani, M. Karamouzis, Y. Janjigian, 2017 .

Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: results of the FFCD 0904 phase II trial.

A. Lièvre, C. Lepage, X. Mirabel, 2023, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial.

M. Ducreux, P. Rougier, J. Breau, 2006, Gastroenterologie clinique et biologique.

Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial

C. Lepage, R. Guimbaud, O. Bouché, 2018, Gastric Cancer.

Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase II study with panitumumab (FFCD 0904).

N. Magné, A. Lièvre, W. Cacheux, 2019, Journal of Clinical Oncology.

46 Randomized phase II trial of LV5FU2, LV5FU2-cisplatinum or LV5FU2-irinotecan in patients (pts) with metastatic gastric or cardial adenocarcinoma (MGA): final results of study FFCD 9803

D. Arsène, O. Bouché, J. Raoul, 2003 .

[Gastroduodenal invagination. Radio-endoscopic aspects].

J. Raoul, J. Bretagne, M. Ramée, 1990, Gastroenterologie clinique et biologique.

FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Results of the FFCD 1102 phase II trial.

C. Lepage, P. Rougier, M. Hebbar, 2016 .

Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial.

S Michiels, J. Pignon, M. Ducreux, 2013, European journal of cancer.

Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial

J. Pignon, M. Ducreux, C. Lepage, 2019, Expert review of pharmacoeconomics & outcomes research.

[Contribution of 131I MIBG scintigraphy in the diagnosis of carcinoid tumors of the digestive tract. Experience of 14 cases].

L. Siproudhis, J. Raoul, P. Bourguet, 1991, Gastroenterologie clinique et biologique.

T. Conroy, S. Gourgou-Bourgade, C. Hennequin, 2009, Journal of Clinical Oncology.

Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma

C. Lombard-Bohas, A. Bertaut, F. Ghiringhelli, 2020, Cancers.

FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial.

C. Lepage, F. Ghiringhelli, J. Raoul, 2018, European journal of cancer.

L. Mineur, A. Kramar, A. Adenis, 2016, BMC Cancer.

PRODIGE 2 phase III trial neoadjuvant in rectal cancer: Quality of life and results at 5 years.

T. Conroy, P. Rouanet, O. Bouché, 2016 .

306 Optimox study: Folfox7 compared to folfox4 in metastatic colorectal cancer (CRC). Results of a randomized study

A. Figer, F. Rivera, A. Gramont, 2003 .

PRODIGE 20: Bevacizumab + chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)--A randomized phase II trial.

O. Bouché, F. Retornaz, J. Taieb, 2015 .